Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of CB03-154 in Healthy Subjects
NCT05502549Phase 1Completed
- Sponsor
- Zhimeng Biopharma
- Start
- Nov 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CB03-154 in epilepsy (15 arms), sponsored by Zhimeng Biopharma. Primary endpoint: Safety and Tolerability of CB03-154. Started Nov 2022; status: completed.
02
Drugs
CB03-154
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05502549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05502549.